Using MRI to study kidney disease and its complications
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Patients With Kidney Disease
This study is testing if a special type of MRI can help find out more about kidney problems and their effects on heart health in people with acute kidney injury and chronic kidney disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Edinburgh Academic / other |
| Locations | 1 site (Edinburgh) |
| Trial ID | NCT06698614 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the potential of manganese-enhanced magnetic resonance imaging (MEMRI) as a biomarker for acute kidney injury (AKI) and its associated cardiovascular and renal complications. The study will involve blood and urine tests, as well as cardiovascular analysis, to assess the relationship between kidney health and cardiovascular disease. Participants will include individuals diagnosed with AKI and chronic kidney disease (CKD), with the goal of identifying those at risk for further complications. The study will be conducted at NHS Lothian in Edinburgh.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a diagnosis of acute kidney injury or stable chronic kidney disease.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker for predicting cardiovascular disease in patients with kidney conditions.
How similar studies have performed: While the use of MEMRI is a novel approach, preliminary data suggest potential success in similar applications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All subjects to be entered must: Be able to provide written informed consent after having received oral and written information about the study. \>18 years of age Availability to complete study visits If female, be non-pregnant as evidenced by a negative pregnancy test or be post-menopausal or surgically sterile. Additionally, cohort specific inclusion criteria are as follows: Cohort 1; Acute kidney injury- A diagnosis of AKI will be made based on the following criteria (based on the definition used in the Kidney Precision Medicine Project www.kpmp.org): Previous (within 3 years) eGFR \>45 ml/min/1.73m2 OR no history of kidney disease if no blood results available AND Elevated creatinine \>1.5x previous result OR \>150 μmol/L if no previous value AND Increasing creatinine within 48 hours OR requirement for dialysis. Cohort 2; Chronic kidney disease- Stable CKD for at least 6 months (monitored by eGFR), matched to AKI cohort at follow up based on renal function. Cohort 3: Matched controls- Matched to AKI cohort participants at baseline for age, sex, cardiovascular disease risk and cardiovascular medication. Cohort 4; Vasculitis- A new diagnosis of vasculitis or an existing diagnosis with relapsing disease, and kidney involvement. Cohort 5; Kidney transplantation- Has kidney failure and has received a kidney transplant in the preceding 1 month. Cohort 6: Kidney transplant rejection- Biopsy proven episode of transplant rejection. Exclusion Criteria: The following criteria apply to all patients: 1. Unable to give informed consent. 2. Have any contraindications to standard MRI safety criteria, including implanted devices. 3. Subjects under the age of 18 years old. 4. Pregnancy/positive pregnancy test. 5. Current breastfeeding. 6. Have a diagnosis of kidney disease due to polycystic kidney disease. 7. Patients in critical care or on surgical wards will be excluded. 8. Patients taking calcium channel antagonists or digoxin. Additionally, cohort specific exclusion criteria are as follow: Cohort 1- Excluded if they have a diagnosis of diabetes. Cohort 2- Excluded if receiving dialysis or those with a functional kidney transplant, multi-system disorders (e.g., systemic vasculitis), or any patients receiving immunosuppression.
Where this trial is running
Edinburgh
- NHS Lothian — Edinburgh, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Hannah Preston, MBCHb
- Email: v1hprest@ed.ac.uk
- Phone: 447889742171
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.